Rathbones Group PLC Sells 5,877 Shares of Guardant Health, Inc. $GH

Rathbones Group PLC decreased its position in Guardant Health, Inc. (NASDAQ:GH) by 2.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,088 shares of the company’s stock after selling 5,877 shares during the period. Rathbones Group PLC owned approximately 0.16% of Guardant Health worth $12,501,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Emerald Advisers LLC boosted its stake in Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after purchasing an additional 173,281 shares during the last quarter. Knights of Columbus Asset Advisors LLC purchased a new position in shares of Guardant Health in the third quarter worth $1,554,000. Edgestream Partners L.P. raised its stake in shares of Guardant Health by 147.3% in the second quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock worth $2,629,000 after purchasing an additional 30,094 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Guardant Health by 54.4% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after purchasing an additional 106,263 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of Guardant Health during the second quarter valued at $567,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Robert W. Baird assumed coverage on Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price objective for the company. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. Canaccord Genuity Group raised their price target on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Leerink Partners lifted their price target on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Finally, Morgan Stanley boosted their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Twenty-one research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $122.57.

Guardant Health Stock Performance

GH stock opened at $91.20 on Monday. The company has a market cap of $11.96 billion, a price-to-earnings ratio of -27.55 and a beta of 1.67. The business’s 50-day moving average is $105.29 and its two-hundred day moving average is $89.12. Guardant Health, Inc. has a fifty-two week low of $34.88 and a fifty-two week high of $120.74.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the prior year, the company posted ($0.62) EPS. The firm’s revenue for the quarter was up 39.4% on a year-over-year basis. Equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Activity at Guardant Health

In other news, CTO Darya Chudova sold 5,451 shares of Guardant Health stock in a transaction on Monday, December 15th. The shares were sold at an average price of $104.04, for a total transaction of $567,122.04. Following the transaction, the chief technology officer owned 7,012 shares in the company, valued at $729,528.48. This trade represents a 43.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the sale, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 114,734 shares of company stock worth $12,083,490. 6.10% of the stock is owned by company insiders.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.